An APP gene test looks for harmful variants in the APP gene in younger adults with memory problems. It measures one inherited cause of early-onset Alzheimer's and misses most other causes, so a negative result cannot clear you alone. The APP gene carries instructions for amyloid precursor protein, which enzymes cut into fragments including amyloid-beta linked to Alzheimer's brain changes, according to MedlinePlus Genetics MedlinePlus guide to the APP gene. Many APP variants can start symptoms before age 65, yet they account for less than 10% of all early-onset cases.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the test measures
- Who may be offered testing?
- What a negative result misses
- What results cannot tell you
What the test measures
The test reads the coding sequence of APP, most often alongside PSEN1 and PSEN2, to confirm an inherited cause in a person with symptoms or with family risk, according to ARUP Consult ARUP Consult overview of the early-onset panel. It uses massively parallel sequencing focused on coding regions and nearby exon boundaries.
Familial early-onset Alzheimer's can come from variants in APP, PSEN1, or PSEN2, according to MedlinePlus Genetics. Those variants pass parent-to-child in an autosomal-dominant pattern, so one copy can carry risk. A positive APP finding points to that inherited path, not to common late-life memory loss.
Who may be offered testing?
Clinicians do not use genetic tests routinely for diagnosis or risk prediction, but a neurologist may order APP, PSEN1, and PSEN2 testing for early-age symptoms with a strong family history, according to the National Institute on Aging NIA genetics fact sheet. The key filters are age at start and family pattern.
Bring ages at symptom start, relationship details, and any prior genetic reports to the neurology visit. That history helps the doctor decide if panel testing fits.
- Memory or thinking symptoms that began at or before age 65
- One or more close blood relatives with early-onset dementia
- A known APP, PSEN1, or PSEN2 variant in the family
- Symptoms after age 65 point away from this test, ARUP Consult advises against ordering it then
What a negative result misses
ARUP Consult reports clinical sensitivity of 60-80% for familial early-onset disease, with APP explaining about 10-15%, PSEN1 about 20-70%, and PSEN2 about 5%. That leaves a large share tied to other or still unknown factors.
A negative APP-inclusive result does not exclude heritable early-onset Alzheimer's, according to the ARUP Laboratories sample report. The method misses unknown genes, variants outside coding regions, and some structural changes. Families with a clear early-onset pattern may still need clinical follow-up and referral to genetics.
What results cannot tell you
The result does not predict onset age, severity, symptom type, or rate of decline. Two people with the same variant can have different courses.
Testing also does not by itself change treatment or prevent onset, according to Blue Cross NC medical policy AHS-M2038 citing Sherva and Kowall 2023, which limits its day-to-day medical use. Its main value is clarifying inheritance, guiding family screening choices, and informing care planning. Ask for genetic counseling before and after testing to review privacy, family impact, and next steps.
